Newly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share clinical experience and patient case examples WESTMINSTER, Colo. --(BUSINESS WIRE)--Jun.
Generated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader market penetration Published landmark, real-world PEDD ® Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure
Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance despite greater baseline clinical complexity WESTMINSTER, Colo.
WESTMINSTER, Colo. --(BUSINESS WIRE)--May 4, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid
Conference Call and Webcast Scheduled for Tuesday, May 12, 2026 at 4:30 PM WESTMINSTER, Colo. --(BUSINESS WIRE)--Apr. 28, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its
WESTMINSTER, Colo. --(BUSINESS WIRE)--Apr. 9, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid
WESTMINSTER, Colo. --(BUSINESS WIRE)--Apr. 7, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid
DENVER --(BUSINESS WIRE)--Mar. 18, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today
Reports $13.2 million i n Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the Prior Year Periods Reaffirms 2026 Revenue Guidance of $60-62 million Strengthened Balance Sheet with $46 Million Gross Proceeds from Recent
Conference Call and Webcast Scheduled for Thursday, March 5, 2026 at 4:30 PM WESTMINSTER, Colo. --(BUSINESS WIRE)--Feb. 25, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies